Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1206 and Pembrolizumab in Advanced Solid Tumors
NCT04219254Phase 2Recruiting
- Sponsor
- BioInvent International
- Start
- Jun 2020
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of BI-1206 in solid tumor, non-small cell lung cancer (NSCLC), Uveal melanoma (UM), sponsored by BioInvent International. Started Jun 2020; status: recruiting.
02
Drugs
BI-1206
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04219254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219254.